Literature DB >> 30243924

An updated Alzheimer hypothesis: Complement C3 and risk of Alzheimer's disease-A cohort study of 95,442 individuals.

Katrine Laura Rasmussen1, Børge Grønne Nordestgaard2, Ruth Frikke-Schmidt3, Sune Fallgaard Nielsen4.   

Abstract

INTRODUCTION: We tested the hypothesis that low plasma complement C3 is observationally and genetically associated with high risk of Alzheimer's disease (AD).
METHODS: We studied 95,442 individuals enrolled in the Copenhagen General Population Study. In genetic analyses, we further included 8367 individuals from the Copenhagen City Heart Study. In the two studies, 1189 and 35 developed AD during median 8 years follow-up.
RESULTS: The multifactorially adjusted hazard ratio for risk of AD for a one standard deviation lower levels of complement C3 was 1.11 (95% confidence interval: 1.04-1.19) in all individuals and 1.66 (1.33-2.07) in APOE ε44 carriers. In Mendelian randomization, the corresponding genetic estimates were 1.66 (1.05-2.63) overall and 1.99 (0.52-7.65) in APOE ε44 carriers. DISCUSSION: Low baseline levels of complement C3 were associated with high risk of AD. The risk was amplified in APOE ε44 highly susceptible individuals, and these findings were substantiated by a Mendelian randomization approach, potentially implying causality. Based on these findings, we present and thoroughly discuss an updated Alzheimer hypothesis incorporating low complement C3 levels.
Copyright © 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APOE; Alzheimer's disease; Complement C3; Genetics; Mendelian randomization

Mesh:

Substances:

Year:  2018        PMID: 30243924     DOI: 10.1016/j.jalz.2018.07.223

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  16 in total

1.  Systemic inflammatory markers in relation to cognitive function and measures of brain atrophy: a Mendelian randomization study.

Authors:  Jiao Luo; Saskia le Cessie; Gerard Jan Blauw; Claudio Franceschi; Raymond Noordam; Diana van Heemst
Journal:  Geroscience       Date:  2022-06-11       Impact factor: 7.713

2.  Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.

Authors:  Sarah M Carpanini; Megan Torvell; Ryan J Bevan; Robert A J Byrne; Nikoleta Daskoulidou; Takashi Saito; Takaomi C Saido; Philip R Taylor; Timothy R Hughes; Wioleta M Zelek; B Paul Morgan
Journal:  Acta Neuropathol Commun       Date:  2022-07-06       Impact factor: 7.578

Review 3.  Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.

Authors:  Sarah M Carpanini; Megan Torvell; Bryan Paul Morgan
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

Review 4.  Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus.

Authors:  Kyumin Shim; Rayhana Begum; Catherine Yang; Hongbin Wang
Journal:  World J Diabetes       Date:  2020-01-15

5.  Glucose excursions in type 2 diabetes modulate amyloid-related proteins associated with dementia.

Authors:  Stephen L Atkin; Alexandra E Butler; Abu Saleh Md Moin; Ahmed Al-Qaissi; Thozhukat Sathyapalan
Journal:  J Transl Med       Date:  2021-03-31       Impact factor: 5.531

6.  The complement cascade in Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Saffire H Krance; Che-Yuan Wu; Yi Zou; Huiyan Mao; Sina Toufighi; Xueyin He; Maureen Pakosh; Walter Swardfager
Journal:  Mol Psychiatry       Date:  2019-10-18       Impact factor: 15.992

Review 7.  Neuroprotective versus Neuroinflammatory Roles of Complement: From Development to Disease.

Authors:  Marlene Kanmogne; Robyn S Klein
Journal:  Trends Neurosci       Date:  2020-11-12       Impact factor: 13.837

8.  Traumatic brain injury alters neuropsychiatric symptomatology in all-cause dementia.

Authors:  Michael J C Bray; Lisa N Richey; Barry R Bryant; Akshay Krieg; Sahar Jahed; William Tobolowsky; Christian LoBue; Matthew E Peters
Journal:  Alzheimers Dement       Date:  2021-01-19       Impact factor: 21.566

Review 9.  TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease.

Authors:  Junling Yang; Leslie Wise; Ken-Ichiro Fukuchi
Journal:  Front Immunol       Date:  2020-04-23       Impact factor: 7.561

10.  Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.

Authors:  Liu Shi; Laura M Winchester; Benjamine Y Liu; Richard Killick; Elena M Ribe; Sarah Westwood; Alison L Baird; Noel J Buckley; Shengjun Hong; Valerija Dobricic; Fabian Kilpert; Andre Franke; Steven Kiddle; Martina Sattlecker; Richard Dobson; Antonio Cuadrado; Abdul Hye; Nicholas J Ashton; Angharad R Morgan; Isabelle Bos; Stephanie J B Vos; Mara Ten Kate; Philip Scheltens; Rik Vandenberghe; Silvy Gabel; Karen Meersmans; Sebastiaan Engelborghs; Ellen E De Roeck; Kristel Sleegers; Giovanni B Frisoni; Olivier Blin; Jill C Richardson; Régis Bordet; José L Molinuevo; Lorena Rami; Anders Wallin; Petronella Kettunen; Magda Tsolaki; Frans Verhey; Alberto Lleó; Daniel Alcolea; Julius Popp; Gwendoline Peyratout; Pablo Martinez-Lage; Mikel Tainta; Peter Johannsen; Charlotte E Teunissen; Yvonne Freund-Levi; Lutz Frölich; Cristina Legido-Quigley; Frederik Barkhof; Kaj Blennow; Katrine Laura Rasmussen; Børge Grønne Nordestgaard; Ruth Frikke-Schmidt; Sune Fallgaard Nielsen; Hilkka Soininen; Bruno Vellas; Iwona Kloszewska; Patrizia Mecocci; Henrik Zetterberg; B Paul Morgan; Johannes Streffer; Pieter Jelle Visser; Lars Bertram; Alejo J Nevado-Holgado; Simon Lovestone
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.